



Supplementary Figure S7

A



B



Supplementary Figure S7. SR-Sarc-0002 cells were treated with repotrectinib (250 nM) or trametinib (100 nM) for one and twenty-four hours, and nuclear and cytoplasmic extracts prepared for western blotting analysis. **A.** Densitometry signal of the nuclear and cytoplasmic CIC_L was quantified and nuclear to cytoplasmic ratio was calculated. Resulting values were normalized to the vehicle-treated control. **B.** Densitometry signal of the phosphorylated-P90RSK (detected only in cytoplasmic fraction) was quantified and normalized to the total P90RSK (both detected only in cytoplasmic fraction). Resulting values were normalized to the vehicle-treated control. Repo: repotrectinib, 250 nM. Tram: trametinib, 100 nM.